Current drug treatment, chronic and acute.

The appropriate management of chronic obstructive pulmonary disease (COPD) involves more than taking prescription medicines. The key components have been set out in detail in many treatment guidelines, both national and international. They include the avoidance of identified risk factors, especially tobacco smoking, and the optimization of daily physical activity. This article reviews the key components of the pharmacologic treatment of COPD, both acute and chronic, with an emphasis on those recent studies, which are likely to change practice in the next few years.

• Publication year

  2014

• Venue

  Clinics in Chest Medicine

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ccm.2013.09.009PMID 24507845
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale

  2013cited by this paper
• Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

  2013cited by this paper
• Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

  2013cited by this paper
• Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

  2013cited by this paper
• GOLD 2011 disease severity classification in COPDGene: a prospective cohort study.

  2013cited by this paper
• Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.

  2013cited by this paper
• Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study

  2012cited by this paper
• Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials

  2012cited by this paper
• Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality

  2012cited by this paper
• Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol

  2012cited by this paper
• Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification

  2012cited by this paper
• Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD

  2012cited by this paper
• Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease

  2012cited by this paper
• An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

  2012cited by this paper
• Efficacy of indacaterol in the treatment of patients with COPD.

  2011cited by this paper
• Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

  2011cited by this paper
• Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials

  2011cited by this paper
• Roflumilast with long-acting &bgr;2-agonists for COPD: influence of exacerbation history

  2011cited by this paper
• Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study.

  2011cited by this paper
• Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

  2011cited by this paper
• Reported pneumonia in patients with COPD: findings from the INSPIRE study.

  2011cited by this paper
• Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

  2011cited by this paper
• Bias due to withdrawal in long‐term randomised trials in COPD: Evidence from the TORCH study

  2011cited by this paper
• Cardiovascular events in patients with COPD: TORCH Study results

  2010cited by this paper
• Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance

  2010cited by this paper
• Susceptibility to exacerbation in chronic obstructive pulmonary disease.

  2010cited by this paper
• Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease.

  2010cited by this paper
• Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial

  2010cited by this paper
• Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

  2010cited by this paper
• Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease.

  2010cited by this paper
• Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.

  2009cited by this paper
• Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

  2009influential reference
• Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

  2009influential reference
• Budesonide and the risk of pneumonia: a meta-analysis of individual patient data.

  2009cited by this paper
• Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD

  2009cited by this paper
• Development and first validation of the COPD Assessment Test

  2009cited by this paper
• Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

  2009cited by this paper
• Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.

  2009cited by this paper
• Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.

  2009cited by this paper
• Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

  2009cited by this paper
• Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.

  2009cited by this paper
• Global strategy for asthma management and prevention: GINA executive summary

  2008cited by this paper
• One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

  2008cited by this paper
• Drugs (including oxygen) in severe COPD

  2008cited by this paper
• The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide.

  2008cited by this paper
• A PEACE-ful solution to COPD exacerbations?

  2008cited by this paper
• Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial

  2007cited by this paper
• Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

  2007influential reference
• COPD exacerbations: defining their cause and prevention

  2007cited by this paper
• Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

  2007influential reference
• What have we learned from large drug treatment trials in COPD?

  2007cited by this paper
• Tiotropium in Combination with Placebo, Salmeterol, or FluticasoneSalmeterol for Treatment of Chronic Obstructive Pulmonary Disease

  2007cited by this paper
• A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Premature discontinuation of patients: a potential bias in COPD clinical trials

  2007cited by this paper
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.

  2007cited by this paper
• Pooled clinical trial analysis of tiotropium safety.

  2006cited by this paper
• Randomised trial of ambulatory oxygen in oxygen-dependent COPD

  2005cited by this paper
• Physiological changes during symptom recovery from moderate exacerbations of COPD

  2005cited by this paper
• Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease.

  2005influential reference
• Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.

  2005cited by this paper
• Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.

  2005cited by this paper
• Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial

  2005cited by this paper
• Effect of oxygen on recovery from maximal exercise in patients with chronic obstructive pulmonary disease

  2004cited by this paper
• Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

  2004cited by this paper
• Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care.

  2004cited by this paper
• Impact of preventing exacerbations on deterioration of health status in COPD

  2004cited by this paper
• Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update

  2003cited by this paper
• Sleep disordered breathing awoken

  2003cited by this paper
• Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease.

  2003cited by this paper
• Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis

  2003cited by this paper
• Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis

  2003cited by this paper
• Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease.

  2003cited by this paper
• The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study.

  2002cited by this paper
• Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease.

  2001cited by this paper
• Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease

  2001cited by this paper
• Systemic glucocorticoids in severe exacerbations of COPD.

  2001cited by this paper
• Health status deterioration in patients with chronic obstructive pulmonary disease.

  2001cited by this paper
• Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

  2000influential reference
• Chronic obstructive pulmonary disease.

  2000cited by this paper
• LONG-TERM TREATMENT WITH INHALED BUDESONIDE IN PERSONS WITH MILD CHRONIC OBSTRUCTIVE PULMONARY DISEASE WHO CONTINUE SMOKING

  2000cited by this paper
• Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

  2000cited by this paper
• Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.

  1999cited by this paper
• Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue Smoking

  1999cited by this paper
• Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group.

  1999cited by this paper
• Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease

  1999cited by this paper
• Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease.

  1999cited by this paper
• Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease.

  1996cited by this paper
• Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.

  1996cited by this paper
• Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.

  1995cited by this paper
• Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.

  1993cited by this paper
• Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease.

  1989cited by this paper
• Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study.

  1989cited by this paper
• Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.

  1987cited by this paper
• Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial.

  1987cited by this paper
• A Three-Center Study

  1979cited by this paper
• A controlled trial

  1971cited by this paper

• Multi-target natural products as alternatives against oxidative stress in Chronic Obstructive Pulmonary Disease (COPD).

  2019cites this paper
• Evidence Summary: Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

  2019cites this paper
• Evaluation of the visit frequency and the use of questionnaires and indices for COPD: a national survey from the On‐Sint study

  2017cites this paper
• Nano partículas contendo o análogo da mexiletina, JME-173desenvolvimento, caracterização e avaliação farmacológica em modelo de inflamação pulmonar induzida por LPS

  2017cites this paper
• A rational approach to single, dual and triple therapy in COPD

  2016cites this paper
• Traitement pharmacologique de la bronchopneumopathie chronique obstructive à l’état stable

  2016influential citation
• A novel SSAO inhibitor PXS-4728 A suppresses inflammation and fibrosis and improves lung function in experimental chronic obstructive pulmonary disease

  2016cites this paper
• The inhibitor of semicarbazide‐sensitive amine oxidase, PXS‐4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model

  2016cites this paper
• Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD

  2015cites this paper
• Therapeutic effects of LASSBio-596 in an elastase-induced mouse model of emphysema

  2015influential citation
• Effect of inhaled corticosteroids on viral and bacterial infection in chronic obstructive pulmonary disease

  2014cites this paper
• Current treatments for chronic obstructive pulmonary disease (COPD)

  2014cites this paper
• Experience with Inhalational Corticosteroids in a Tertiary Care Center

  2014cites this paper